百诚医药(301096)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301096 百诚医药

已收盘 12-17 15:00:00

{"stockData":{"symbol":"301096","market":"SZ","secType":"STK","nameCN":"百诚医药","latestPrice":53.4,"timestamp":1765955007000,"preClose":53.24,"halted":0,"volume":1612600,"delay":0,"changeRate":0.003,"floatShares":82787200,"shares":109000000,"eps":-1.7237,"marketStatus":"已收盘","change":0.16,"latestTime":"12-17 15:00:00","open":53.19,"high":53.7,"low":51.92,"amount":85047800,"amplitude":0.0334,"askPrice":53.4,"askSize":5,"bidPrice":53.36,"bidSize":3,"shortable":0,"etf":0,"ttmEps":-1.7237,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766021400000},"marketStatusCode":5,"adr":0,"adjPreClose":53.24,"symbolType":"stock","openAndCloseTimeList":[[1765935000000,1765942200000],[1765947600000,1765954800000]],"highLimit":58.56,"lowLimit":47.92,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":109228284,"isCdr":false,"pbRate":2.25,"roa":"--","roe":"0.24%","epsLYR":-0.49,"committee":-0.164659,"marketValue":5833000000,"turnoverRate":0.0195,"status":0,"floatMarketCap":4421000000},"requestUrl":"/m/hq/s/301096/tweets","defaultTab":"tweets","newsList":[{"id":"2591650670","title":"百诚医药最新公告：员工战略配售资管计划拟减持不超0.5077%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2591650670","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591650670?lang=zh_cn&edition=full","pubTime":"2025-12-14 16:20","pubTimestamp":1765700401,"startTime":"0","endTime":"0","summary":"百诚医药(301096.SZ)公告称，持有公司1.0425%股份的股东富诚海富资管—杭州银行—富诚海富通百诚医药员工参与创业板战略配售集合资产管理计划（简称“员工战略配售资管计划”）拟以大宗交易方式或集中竞价交易方式减持本公司股份不超过55.06万股（占公司总股本的0.5077%）。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121400002945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"gpt_icon":0},{"id":"2588053246","title":"百诚医药：12月1日高管宋博凡、严洪兵减持股份合计1100股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588053246","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588053246?lang=zh_cn&edition=full","pubTime":"2025-12-02 21:03","pubTimestamp":1764680630,"startTime":"0","endTime":"0","summary":"证券之星消息，根据12月2日市场公开信息、上市公司公告及交易所披露数据整理，百诚医药最新董监高及相关人员股份变动情况：2025年12月1日公司董事宋博凡、董事严洪兵共减持公司股份1100.0股，占公司总股本为0.001%。变动期间公司股价上涨0.82%，12月1日当日收盘报54.15元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200037357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"gpt_icon":0},{"id":"2585462458","title":"百诚医药：11月21日高管严洪兵减持股份合计1000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2585462458","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585462458?lang=zh_cn&edition=full","pubTime":"2025-11-24 21:02","pubTimestamp":1763989368,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月24日市场公开信息、上市公司公告及交易所披露数据整理，百诚医药最新董监高及相关人员股份变动情况：2025年11月21日公司董事严洪兵共减持公司股份1000.0股，占公司总股本为0.0009%。变动期间公司股价下跌4.33%，11月21日当日收盘报48.8元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400032858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"gpt_icon":0},{"id":"2585149509","title":"百诚医药（301096）发布董事会议事规则，11月21日股价下跌4.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585149509","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585149509?lang=zh_cn&edition=full","pubTime":"2025-11-21 22:26","pubTimestamp":1763735187,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，百诚医药报收于48.8元，较前一交易日下跌4.33%，最新总市值为53.3亿元。该股当日开盘50.88元，最高51.23元，最低48.8元，成交额达1.36亿元，换手率为3.31%。近日，杭州百诚医药科技股份有限公司发布《董事会议事规则》，明确董事会的组成、职权及议事决策程序。根据公告，董事会由9名董事组成，包括3名独立董事和1名职工代表董事，设董事长1名为法定代表人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100040136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"gpt_icon":0},{"id":"2585117460","title":"百诚医药最新公告：与众神创新签署BIOS-0629项目技术开发合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2585117460","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585117460?lang=zh_cn&edition=full","pubTime":"2025-11-21 19:40","pubTimestamp":1763725255,"startTime":"0","endTime":"0","summary":"百诚医药(301096.SZ)公告称，公司与众神创新就1类创新药BIOS-0629项目达成大中华地区（大陆及港澳台地区）独家授权合作并签署了《技术开发合作协议》及补充协议，众神创新根据研发节点支付里程碑款3亿元。合作产品在大中华区上市后，公司另享有销售额10%的提成收益。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100033901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"gpt_icon":0},{"id":"2585819001","title":"11月21日百诚医药创60日新低，华夏国证2000指数增强发起式A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2585819001","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585819001?lang=zh_cn&edition=full","pubTime":"2025-11-21 16:04","pubTimestamp":1763712269,"startTime":"0","endTime":"0","summary":"证券之星消息，11月21日百诚医药创60日新低，收盘报48.8元，当日跌4.33%，换手率3.31%，成交量2.74万手，成交额1.36亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为华夏基金的华夏国证2000指数增强发起式A。华夏国证2000指数增强发起式A目前规模为0.18亿元，最新净值1.2783，较上一交易日下跌0.74%，近一年上涨31.55%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100019172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399303","BK0216","159628","301096"],"gpt_icon":0},{"id":"2584607878","title":"百诚医药：已布局神经生物学等多条新药管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2584607878","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584607878?lang=zh_cn&edition=full","pubTime":"2025-11-18 11:33","pubTimestamp":1763436785,"startTime":"0","endTime":"0","summary":"证券之星消息，百诚医药11月17日在投资者关系平台上答复投资者关心的问题。这一布局如何契合全球创新药研发的主流方向，市场空间有多大？随着全球人口老龄化的加剧，神经退行性疾病患者人数迅速增长，市场需求大。目前公司在神经生物学、自身免疫和肿瘤等领域已布局多条自主研发的新药管线，已取得 3个IND批件的一类新药，10个IND批件的二类新药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800014196.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"gpt_icon":0},{"id":"2583639572","title":"百诚医药最新公告：全资子公司BIOS2242口服溶液获得临床试验批准通知书目前国内外尚无该产品获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2583639572","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583639572?lang=zh_cn&edition=full","pubTime":"2025-11-14 18:19","pubTimestamp":1763115573,"startTime":"0","endTime":"0","summary":"百诚医药(301096.SZ)公告称，全资子公司浙江赛默制药有限公司申报的药品BIOS2242口服溶液获得国家药品监督管理局临床试验批准通知书。该药品用于治疗轻、中度急性缺血性脑卒中，目前国内外尚无该产品获批上市。公司表示，此次获得临床试验批准对近期业绩不会产生重大影响，后续将根据相关规定组织开展临床试验，但存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400030719.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"gpt_icon":0},{"id":"2583550783","title":"百诚医药（301096）披露BIOS-0629项目签署《技术开发合作协议》，11月13日股价上涨0.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583550783","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583550783?lang=zh_cn&edition=full","pubTime":"2025-11-13 17:28","pubTimestamp":1763026112,"startTime":"0","endTime":"0","summary":"截至2025年11月13日收盘，百诚医药报收于54.73元，较前一交易日上涨0.31%，最新总市值为59.78亿元。公司近日发布公告称，杭州百诚医药科技股份有限公司与浙江众神创新医药科技有限公司就BIOS-0629项目签署《技术开发合作协议》。该药物处于PCC阶段，适应症为实体瘤，合作区域为大中华区。百诚医药负责研发、临床试验及注册申报，众神创新负责大中华区内的研发转化、生产销售及市场拓展。协议自双方盖章之日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300030047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"gpt_icon":0},{"id":"2582837564","title":"百诚医药最新公告：与浙江众神创新医药科技签署BIOS-0629项目技术开发合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2582837564","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582837564?lang=zh_cn&edition=full","pubTime":"2025-11-12 20:09","pubTimestamp":1762949395,"startTime":"0","endTime":"0","summary":"百诚医药(301096.SZ)公告称，公司与浙江众神创新医药科技签署《技术开发合作协议》，合作开发BIOS-0629项目，该产品目前处于PCC阶段，适应症为实体瘤。合作区域为大中华区（大陆和港澳台地区），除大中华区域外的权益仍归属于百诚医药。公司负责研究开发、临床试验、注册申报等工作，众神创新负责大中华区域的研发转化、上市后生产销售和市场拓展工作。交易价格为人民币3亿元，结算方式包括里程碑款和销售额提成。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200036938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK1574","09939","159938","BK1161","BK0216","BK1515"],"gpt_icon":0},{"id":"2582487978","title":"百诚医药：11月7日高管严洪兵减持股份合计2000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2582487978","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582487978?lang=zh_cn&edition=full","pubTime":"2025-11-10 21:03","pubTimestamp":1762779810,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月10日市场公开信息、上市公司公告及交易所披露数据整理，百诚医药最新董监高及相关人员股份变动情况：2025年11月7日公司董事严洪兵共减持公司股份2000.0股，占公司总股本为0.0018%。变动期间公司股价下跌2.88%，11月7日当日收盘报52.52元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000032395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"gpt_icon":0},{"id":"2581004450","title":"百诚医药(301096.SZ)：创新药BIOS-0625片获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2581004450","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581004450?lang=zh_cn&edition=full","pubTime":"2025-11-07 20:37","pubTimestamp":1762519076,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百诚医药 发布公告，公司近日获悉，公司自主研发的创新药BIOS-0625片获得国家药品监督管理局临床试验批准通知书。溃疡性结肠炎作为一种慢性复发性肠道炎症性疾病，其\"不可根治、反复发作\"的病程特征构成了持久的治疗挑战。BIOS-0625片是由公司自主研发的一种全新靶点应用于治疗溃疡性结肠炎的药物，目前该靶点暂无同适应症药品上市。BIOS-0625片属于“境内外均未上市的创新药”，其注册分类为化学药品1类。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301096","159992","BK1574","BK1161","BK0216","06978"],"gpt_icon":0},{"id":"2581456744","title":"百诚医药跌9.03% 2021年上市即巅峰超募12亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2581456744","media":"中国经济网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581456744?lang=zh_cn&edition=full","pubTime":"2025-11-05 17:02","pubTimestamp":1762333320,"startTime":"0","endTime":"0","summary":"中国经济网北京11月5日讯百诚医药今日收报55.99元，跌幅9.03%。上市首日，百诚医药创下股价高点120元，为该股上市以来最高价。百诚医药最终募集资金净额比原计划多12.13亿元。百诚医药于2021年12月15日披露的招股说明书显示，该公司拟募集资金6.51亿元，全部用于杭州百诚医药科技股份有限公司总部及研发中心项目。百诚医药首次公开发行股票的发行费用总额为2.89亿元，其中，承销保荐费用2.62亿元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-05/doc-infwiwtq9462348.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-05/doc-infwiwtq9462348.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301096","BK0216"],"gpt_icon":0},{"id":"2581419447","title":"11月5日百诚医药跌9.03%，华夏国证2000指数增强发起式A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2581419447","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581419447?lang=zh_cn&edition=full","pubTime":"2025-11-05 16:40","pubTimestamp":1762332026,"startTime":"0","endTime":"0","summary":"证券之星消息，11月5日百诚医药跌9.03%，收盘报55.99元，换手率23.71%，成交量19.63万手，成交额11.04亿元。重仓百诚医药的公募基金请见下表：该股最近90天内共有6家机构给出评级，买入评级4家，增持评级2家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为华夏基金的华夏国证2000指数增强发起式A。华夏国证2000指数增强发起式A目前规模为0.18亿元，最新净值1.304，较上一交易日下跌1.25%，近一年上涨38.59%。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202511/05/20251105120659.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202511/05/20251105120659.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251105/31769775.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0216","301096","159628","399303"],"gpt_icon":0},{"id":"2581799493","title":"【私募调研记录】鸿道投资调研百诚医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2581799493","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581799493?lang=zh_cn&edition=full","pubTime":"2025-11-05 08:04","pubTimestamp":1762301095,"startTime":"0","endTime":"0","summary":"根据市场公开信息及11月4日披露的机构调研信息，知名私募鸿道投资近期对1家上市公司进行了调研，相关名单如下：1）百诚医药 调研纪要：赛默制药已建成GMP厂房16.3万平方米，完成617个项目验证，申报注册461个。公司已成功发行过鸿道全球优选、创新改革系列等六十几只私募基金产品，是国内知名的私募证券投资基金。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2025110500004930.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"gpt_icon":0},{"id":"2580734344","title":"百诚医药：11月3日高管贾飞、陈安、宋博凡、严洪兵减持股份合计2.86万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2580734344","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580734344?lang=zh_cn&edition=full","pubTime":"2025-11-04 21:03","pubTimestamp":1762261406,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月4日市场公开信息、上市公司公告及交易所披露数据整理，百诚医药最新董监高及相关人员股份变动情况：2025年11月3日公司董事,高管贾飞、高管陈安、董事宋博凡、董事严洪兵共减持公司股份2.86万股，占公司总股本为0.0262%。变动期间公司股价上涨19.15%，11月3日当日收盘报68.99元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400037535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"gpt_icon":0},{"id":"2580788677","title":"11月4日百诚医药跌10.78%，华夏国证2000指数增强发起式A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2580788677","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580788677?lang=zh_cn&edition=full","pubTime":"2025-11-04 16:33","pubTimestamp":1762245214,"startTime":"0","endTime":"0","summary":"证券之星消息，11月4日百诚医药跌10.78%创60日新高，收盘报61.55元，换手率35.83%，成交量29.67万手，成交额20.41亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为华夏基金的华夏国证2000指数增强发起式A。华夏国证2000指数增强发起式A目前规模为0.18亿元，最新净值1.3205，较上一交易日上涨0.2%，近一年上涨43.45%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400025560.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159628","BK0216","399303","301096"],"gpt_icon":0},{"id":"2580727182","title":"百诚医药：冯恩光与张夏衡同任新药启杭论坛评委","url":"https://stock-news.laohu8.com/highlight/detail?id=2580727182","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580727182?lang=zh_cn&edition=full","pubTime":"2025-11-04 11:37","pubTimestamp":1762227429,"startTime":"0","endTime":"0","summary":"投资者提问：据杭高院官方公众号，2022年12月6日百诚的冯恩光博士和杭高院的张夏衡教授一同在活动上发表讲话，请问公司和杭高院的合作中有接触到张夏衡团队吗？百诚医药回复：尊敬的投资者您好，2022年12月6日，在国科大杭州高等研究院举办的第一届“新药启杭”研究生论坛暨百诚医药奖学金活动中，杭高院张夏衡教授、公司新药研发部总经理冯恩光博士等数位专家、教授受邀担任评委，公司董事长楼金芳出席并致辞。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400014827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"gpt_icon":0},{"id":"2580272400","title":"百诚医药：共建糖类药物重点实验室","url":"https://stock-news.laohu8.com/highlight/detail?id=2580272400","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580272400?lang=zh_cn&edition=full","pubTime":"2025-11-04 11:37","pubTimestamp":1762227428,"startTime":"0","endTime":"0","summary":"证券之星消息，百诚医药11月03日在投资者关系平台上答复投资者关心的问题。百诚医药回复：尊敬的投资者您好，公司自2022年开始与国科大杭州高等研究院共同设立生物医药联合研发中心，双方共建的“全省糖类药物重点实验室”被评为2024年浙江省重点实验室。以杭高院的科研技术为主导，结合百诚医药的产业链资源，共同致力于生命健康领域的技术开发与应用，聚焦于肿瘤、免疫、神经系统调节、抗感染和呼吸道等多个领域创新药研发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400014826.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"gpt_icon":0},{"id":"2580213119","title":"百诚医药：10月31日高管严洪兵减持股份合计500股","url":"https://stock-news.laohu8.com/highlight/detail?id=2580213119","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580213119?lang=zh_cn&edition=full","pubTime":"2025-11-03 21:03","pubTimestamp":1762174995,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月3日市场公开信息、上市公司公告及交易所披露数据整理，百诚医药最新董监高及相关人员股份变动情况：2025年10月31日公司董事严洪兵共减持公司股份500.0股，占公司总股本为0.0005%。变动期间公司股价上涨4.34%，10月31日当日收盘报57.9元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300033744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765967157826,"stockEarnings":[{"period":"1week","weight":-0.0108},{"period":"1month","weight":-0.0139},{"period":"3month","weight":-0.1409},{"period":"6month","weight":0.2598},{"period":"1year","weight":0.2957},{"period":"ytd","weight":0.4033}],"compareEarnings":[{"period":"1week","weight":-0.0217},{"period":"1month","weight":-0.0415},{"period":"3month","weight":-0.0133},{"period":"6month","weight":0.1376},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.1411}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"杭州百诚医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"10081人(较上一季度减少15.05%)","perCapita":"8212股","listingDate":"2021-12-20","address":"浙江省杭州市临平区临平街道绿洲路159号","registeredCapital":"10922万元","survey":"　　杭州百诚医药科技股份有限公司的主营业务是为各类制药企业、医药研发投资企业提供：医药技术受托研发服务（CRO业务）、研发技术成果转化服务、定制研发生产服务（CDMO）。公司的主要产品是临床前药学研究、研发技术成果转化、临床服务、CDMO、权益分成及其他。","listedPrice":79.6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百诚医药(301096)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百诚医药(301096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百诚医药,301096,百诚医药股票,百诚医药股票老虎,百诚医药股票老虎国际,百诚医药行情,百诚医药股票行情,百诚医药股价,百诚医药股市,百诚医药股票价格,百诚医药股票交易,百诚医药股票购买,百诚医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百诚医药(301096)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百诚医药(301096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}